Genes That Determine Immunology and Inflammation Modify the Basic Defect of Impaired Ion Conductance in Cystic Fibrosis Epithelia

Overview

Journal J Med Genet

Specialty Genetics

Date 2010 Sep 15

PMID 20837493

Citations 38

Authors

Frauke Stanke

Tim Becker

Vinod Kumar

Silke Hedtfeld

Christian Becker

Harry Cuppens

Stephanie Tamm

Jennifer Yarden

Ulrike Laabs

Benny Siebert

Luis Fernandez

Milan Macek Jr

Dragica Radojkovic

Manfred Ballmann

Joachim Greipel

Jean-Jacques Cassiman

Thomas F Wienker

Burkhard Tummler

Affiliations

Soon will be listed here.

Abstract

Background: The cystic fibrosis (CF) basic defect, caused by dysfunction of the apical chloride channel CFTR in the gastrointestinal and respiratory tract epithelia, has not been employed so far to support the role of CF modifier genes.

Methods: Patients were selected from 101 families with a total of 171 F508del-CFTR homozygous CF patients to identify CF modifying genes. A candidate gene based association study of 52 genes on 16 different chromosomes with a total of 182 genetic markers was performed. Differences in haplotype and/or diplotype distribution between case and reference CF subpopulations were analysed.

Results: Variants at immunologically relevant genes were associated with the manifestation of the CF basic defect (0.01<Praw<0.0001 at IL1B, TLR9, TNFα, CD95, STAT3 and TNFR). The intragenic background of F508del-CFTR chromosomes determined disease severity and manifestation of the basic defect (Praw=0.0009). Allele distributions comparing transmitted and non-transmitted alleles were distorted at several loci unlinked to CFTR.

Conclusions: The inherited capabilities of the innate and adaptive immune system determine the manifestation of the CF basic defect. Variants on F508del-CFTR chromosomes contribute to the observed patient-to-patient variability among F508del-CFTR homozygotes. A survivor effect, manifesting as a transmission disequilibrium at many loci, is consistent with the improvement of clinical care over the last decades, resulting in a depletion of risk alleles at modifier genes. Awareness of non-genetic factors such as improvement of patient care over time is crucial for the interpretation of CF modifier studies.

Citing Articles

Evaluating precision medicine tools in cystic fibrosis for racial and ethnic fairness.

Colegate S, Palipana A, Gecili E, Szczesniak R, Brokamp C J Clin Transl Sci. 2024; 8(1):e94.

PMID: 39220818 PMC: 11362628. DOI: 10.1017/cts.2024.532.

IL1B gene variants, but not TNF, CXCL8, IL6 and IL10, modify the course of cystic fibrosis in Polish patients.

Zakerska-Banaszak O, Gozdzik-Spychalska J, Gabryel M, Zuraszek J, Skrzypczak-Zielinska M, Slomski R F1000Res. 2024; 11:379.

PMID: 39185143 PMC: 11344199. DOI: 10.12688/f1000research.110472.3.

Lung Inflammatory Genes in Cystic Fibrosis and Their Relevance to Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapies.

Carbone A, Vitullo P, Di Gioia S, Conese M Genes (Basel). 2023; 14(10).

PMID: 37895314 PMC: 10606852. DOI: 10.3390/genes14101966.

Analysis of CF patient survival confirms STAT3 as a CF-modifying gene with changing impact over time.

Dunsche I, Raddatz E, Ismer H, Hedtfeld S, Tamm S, Moser S Hum Mol Genet. 2022; 32(4):543-550.

PMID: 36048831 PMC: 9896460. DOI: 10.1093/hmg/ddac221.

The first report on CFTR mutations of meconium ileus in cystic fibrosis population in Saudi Arabia: A single center review.

Banjar H, Qeretli R, Ramadan A, Al-Ibraheem A, Bnatig F Int J Pediatr Adolesc Med. 2022; 9(1):32-35.

PMID: 35573065 PMC: 9072234. DOI: 10.1016/j.ijpam.2021.03.008.

References

Mekus F, Laabs U, Veeze H, Tummler B . Genes in the vicinity of CFTR modulate the cystic fibrosis phenotype in highly concordant or discordant F508del homozygous sib pairs. Hum Genet. 2002; 112(1):1-11. DOI: 10.1007/s00439-002-0839-7. View

Becker T, Jansen S, Tamm S, Wienker T, Tummler B, Stanke F . Transmission ratio distortion and maternal effects confound the analysis of modulators of cystic fibrosis disease severity on 19q13. Eur J Hum Genet. 2007; 15(7):774-8. DOI: 10.1038/sj.ejhg.5201825. View

De Jonge H, Ballmann M, Veeze H, Bronsveld I, Stanke F, Tummler B . Ex vivo CF diagnosis by intestinal current measurements (ICM) in small aperture, circulating Ussing chambers. J Cyst Fibros. 2004; 3 Suppl 2:159-63. DOI: 10.1016/j.jcf.2004.05.034. View

Quinton H, OConnor G . Current issues in quality improvement in cystic fibrosis. Clin Chest Med. 2007; 28(2):459-72. DOI: 10.1016/j.ccm.2007.02.013. View

Davis P . Cystic fibrosis since 1938. Am J Respir Crit Care Med. 2005; 173(5):475-82. DOI: 10.1164/rccm.200505-840OE. View

Frazer K, Ballinger D, Cox D, Hinds D, Stuve L, Boudreau A . A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007; 449(7164):851-61. PMC: 2689609. DOI: 10.1038/nature06258. View

Zielenski J, Corey M, Rozmahel R, Markiewicz D, Aznarez I, Casals T . Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13. Nat Genet. 1999; 22(2):128-9. DOI: 10.1038/9635. View

Herold C, Becker T . Genetic association analysis with FAMHAP: a major program update. Bioinformatics. 2008; 25(1):134-6. DOI: 10.1093/bioinformatics/btn581. View

Stanke F, Becker T, Hedtfeld S, Tamm S, Wienker T, Tummler B . Hierarchical fine mapping of the cystic fibrosis modifier locus on 19q13 identifies an association with two elements near the genes CEACAM3 and CEACAM6. Hum Genet. 2010; 127(4):383-94. DOI: 10.1007/s00439-009-0779-6. View

10.

Bronsveld I, Mekus F, Bijman J, Ballmann M, de Jonge H, Laabs U . Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings. J Clin Invest. 2001; 108(11):1705-15. PMC: 200980. DOI: 10.1172/JCI12108. View

11.

Galietta L, Folli C, Caci E, Pedemonte N, Taddei A, Ravazzolo R . Effect of inflammatory stimuli on airway ion transport. Proc Am Thorac Soc. 2005; 1(1):62-5. DOI: 10.1513/pats.2306017. View

12.

Koch C, Cuppens H, Rainisio M, Madessani U, Harms H, Hodson M . European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulmonol. 2001; 31(1):1-12. DOI: 10.1002/1099-0496(200101)31:1<1::aid-ppul1000>3.0.co;2-t. View

13.

Bremer L, Blackman S, Vanscoy L, McDougal K, Bowers A, Naughton K . Interaction between a novel TGFB1 haplotype and CFTR genotype is associated with improved lung function in cystic fibrosis. Hum Mol Genet. 2008; 17(14):2228-37. PMC: 2902288. DOI: 10.1093/hmg/ddn123. View

14.

Bronsveld I, Mekus F, Bijman J, Ballmann M, Greipel J, Hundrieser J . Residual chloride secretion in intestinal tissue of deltaF508 homozygous twins and siblings with cystic fibrosis. The European CF Twin and Sibling Study Consortium. Gastroenterology. 2000; 119(1):32-40. DOI: 10.1053/gast.2000.8524. View

15.

Spielman R, McGinnis R, Ewens W . Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet. 1993; 52(3):506-16. PMC: 1682161. View

16.

Eisenhut M . Reduction of alveolar epithelial ion and fluid transport by inflammatory mediators. Am J Respir Cell Mol Biol. 2007; 36(3):388-9. DOI: 10.1165/ajrcmb.36.3.388. View

17.

Frank J, Roux J, Kawakatsu H, Su G, Dagenais A, Berthiaume Y . Transforming growth factor-beta1 decreases expression of the epithelial sodium channel alphaENaC and alveolar epithelial vectorial sodium and fluid transport via an ERK1/2-dependent mechanism. J Biol Chem. 2003; 278(45):43939-50. DOI: 10.1074/jbc.M304882200. View

18.

Rowntree R, Harris A . DNA polymorphisms in potential regulatory elements of the CFTR gene alter transcription factor binding. Hum Genet. 2002; 111(1):66-74. DOI: 10.1007/s00439-002-0737-z. View

19.

Becker T, Knapp M . A powerful strategy to account for multiple testing in the context of haplotype analysis. Am J Hum Genet. 2004; 75(4):561-70. PMC: 1182044. DOI: 10.1086/424390. View

20.

Sharma R, Florea V, Bolger A, Doehner W, Florea N, Coats A . Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax. 2001; 56(10):746-50. PMC: 1745930. DOI: 10.1136/thorax.56.10.746. View